New study checks liver impact on myeloma drug combo

This early-phase study looks at how the drug combination BVd (belantamab mafodotin, bortezomib, and dexamethasone) is processed by the body in people with multiple myeloma who also have moderate liver problems. About 20 participants will be enrolled to compare drug levels and safety between those with and without liver issues. The goal is to find the right dose for patients with liver impairment.